Some people advocate giving Alzheimer's disease drugs to people with normal cognitive function who have elevated amyloid levels in their brains. This is not only wrong, but dangerous.

Aducanumab has just been approved by the Food and Drug Administration to slow the progress of Alzheimer’s disease. It is likely that many people who are candidates for the drug will no longer be competent to make their own health care decisions, and will be relying heavily on others to make the decision with them or for them. As a layperson, how would I evaluate the risks and benefits of this drug, were I acting as a health care proxy for someone with Alzheimer’s disease?

June 7, 2021, was a bad day for science. That was the day Food and Drug Administration approved aducanumab for the treatment of Alzheimer’s disease, even though a committee of its own selected experts recommended strongly against approval.

Newly published first-person stories of the challenges, struggles, and joys of providing care for family members or another close person with Alzheimer's disease and other types of dementia "depict humanity on the brink."